|View printer-friendly version|
Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences
The most recent Compendium update adds gastric and liver models, as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer. The newest additions to the Compendium provide oncology researchers access to data that allows them to identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.
The Compendium includes tumor models from a wide range of tumor subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models.
Presence at Scientific Conferences
The Compendium is just one example of Charles River’s commitment to
oncology research. Charles River experts presented four posters at the
Society for Immunotherapy’s (
Noteworthy posters include:
Modulation of adenosine levels in the tumor microenvironment
following treatment with anti-PD1 antibodies and oxaliplatin: an in
vivo microdialysis study (Presented at SITC’s 33rd
Annual Meeting by
Arash Rassoulpour) Utilizing in vivo microdialysis, a technique that has been prominent in neuroscience research for over 50 years, Charles River researchers monitored oncometabolites and immunomodulators directly in the tumor microenvironment.
Development of a disseminated AML mouse model to evaluate the
therapeutic activity of immune checkpoint inhibitors using
bioluminescence imaging (To be presented at EORTC by
David Harris) Charles River researchers developed a disseminated AML disease model to evaluate the therapeutic response to immune checkpoint inhibitors, PD-1, PD-L1 and CTLA-4.
A full schedule of Charles River’s activities during SITC’s 33rd Annual Meeting and EORTC is available online, with poster reprint available after the conferences. Reprints of posters presented at EORTC will also be available in booth A2 during the show.
- “The power of our oncology portfolio is stronger than ever. Our scientists have worked diligently to accelerate cancer research and anticancer drug development efforts so patients can get the treatments they desperately need.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
- “Since its inception, our Tumor Model Compendium has made finding the best research model for oncology research easier. We are excited about the latest additions and are proud to offer this important resource to oncology researchers.” –Julia Schueler, Research Director, Charles River
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Todd Spencer, 781-222-6455
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations